Clinically validated in an international study, QR678 Neo® delivers 43 per cent better hair transplant results, redefining graft survival and patient outcomes

QR678 Neo, a patented Indian-developed biomimetic peptide formulation, has been clinically validated through a global study as a breakthrough in hair transplant surgery. Published in the Journal of Cosmetic and Laser Therapy, the study confirms that QR678 Neo improves graft survival by 43 per cent, enhances density, and delivers visibly superior hair regrowth compared to traditional methods.

The international trial involved 112 men with advanced hair loss and was led by experts from India, the USA, and Malaysia. Unlike traditional storage mediums such as saline or PRP, which provide only temporary follicle support, QR678 Neo plays an active biological role before, during, and after surgery protecting grafts, nourishing the scalp, and accelerating recovery.

Dr. Michael Gold, Lead Investigator from the USA, said, "What stood out in this study was not just the improvement in hair regrowth, but the consistency of results across patients and clinical settings. Biologically active therapies like QR678 Neo support graft survival in ways that traditional methods haven't."

Dr. Ungku Shahrin from Malaysia added, "Hair restoration surgery has long needed an intervention that could raise global results. With QR678 Neo, we've moved beyond cosmetic outcomes to reproducible, clinically validated results."

Highlighting its impact, Dr. Mahesh Gosavi from India stated, "Patients are experiencing faster recovery, fewer repeat surgeries, and greater confidence." Meanwhile, Dr. Vinay Chouksey emphasized that QR678 Neo represents India's leadership in biotech-driven healthcare, validated by more than 14 clinical trials worldwide.

With the global hair restoration market surpassing USD4 billion, QR678 Neo marks a pivotal advance, setting a new global standard for minimally invasive, regenerative hair therapy.